Patents by Inventor Menno Van Lookeren Campagne

Menno Van Lookeren Campagne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized Anti-Factor D Antibodies And Uses Thereof
    Publication number: 20140212433
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 31, 2014
    Applicant: Genentech, Inc.
    Inventors: ARTHUR HUANG, ROBERT KELLEY, HENRY LOWMAN, MENNO VAN LOOKEREN CAMPAGNE, CHARLES WINTER
  • HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF
    Publication number: 20140065137
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: September 20, 2013
    Publication date: March 6, 2014
    Applicant: GENENTECH, INC.
    Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • Polynucleotides encoding humanized anti-factor D antibodies
    Patent number: 8614306
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: December 24, 2013
    Assignee: Genentech, Inc.
    Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20130302333
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 14, 2013
    Applicant: GENENTECH, INC.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Weismann, Menno Van Lookeren Campagne
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8497094
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 30, 2013
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20130052685
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: July 20, 2012
    Publication date: February 28, 2013
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • C3b antibodies and methods for the prevention and treatment of complement-associated disorders
    Patent number: 8377437
    Abstract: The present invention concerns antibodies to c3b and the prevention and treatment of complement-associated disorder using such antibodies.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: February 19, 2013
    Assignee: Genentech, Inc.
    Inventor: Menno Van Lookeren Campagne
  • HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF
    Publication number: 20120328613
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: August 22, 2012
    Publication date: December 27, 2012
    Applicant: GENENTECH, INC.
    Inventors: ARTHUR HUANG, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • Humanized anti-factor D antibodies and uses thereof
    Patent number: 8273352
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: September 25, 2012
    Assignee: Genentech, Inc.
    Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8268310
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: September 18, 2012
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Anti-factor B antibodies and their uses
    Publication number: 20120230997
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists.
    Type: Application
    Filed: January 31, 2012
    Publication date: September 13, 2012
    Inventors: Menno Van Lookeren Campagne, Laura Deforge
  • C3b antibodies and methods for the prevention and treatment of complement-associated disorders
    Publication number: 20120128674
    Abstract: The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies.
    Type: Application
    Filed: July 18, 2011
    Publication date: May 24, 2012
    Inventor: Menno Van Lookeren Campagne
  • DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DEMYELINATING DISEASES
    Publication number: 20120128698
    Abstract: The present invention concerns the diagnosis and treatment of autoimmune demyelinating diseases, such as multiple sclerosis (MS), by means of a CLM-I agonist.
    Type: Application
    Filed: July 2, 2010
    Publication date: May 24, 2012
    Inventor: Menno van Lookeren Campagne
  • Anti-factor B antibodies and their uses
    Patent number: 8158762
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: April 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Menno Van Lookeren Campagne, Laura Deforge
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20110282034
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: July 22, 2011
    Publication date: November 17, 2011
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • C3b antibodies and methods for the prevention and treatment of complement-associated disorders
    Patent number: 8012473
    Abstract: The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: September 6, 2011
    Assignee: Genentech, Inc.
    Inventor: Menno Van Lookeren Campagne
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8007791
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: August 30, 2011
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Co-crystal structure of factor D and anti-factor D antibody
    Publication number: 20110165648
    Abstract: The present invention is directed towards the co-crystal structure of Factor D and an anti-Factor D antibody or an antigen binding fragment thereof.
    Type: Application
    Filed: November 3, 2010
    Publication date: July 7, 2011
    Inventors: Menno Van Lookeren Campagne, Christian Wiesmann
  • Crystal structure of CRIg and C3b:CRIg complex
    Patent number: 7930109
    Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: April 19, 2011
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Jianping Yin, Kenneth Katschke, Micah Steffek, Menno Van Lookeren Campagne, Christian Wiesmann
  • Crystal Structure of CRIg and C3B:CRIg Complex
    Publication number: 20100291694
    Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
    Type: Application
    Filed: December 14, 2009
    Publication date: November 18, 2010
    Inventors: Philip Hass, Jianping Yin, Kenneth Katschke, Micah Steffek, Menno Van Lookeren Campagne, Christian Wiesmann